![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pharmacokinetics and Safety of Pan-Genotypic, Direct Acting Protease Inhibitor, ABT-493, and NS5A Inhibitor, ABT-530, Following 3 Day Monotherapy in HCV Genotype-1 Infected Subjects With or Without Compensated Cirrhosis
|
|
|
Reported by jules Levin
AASLD Nov 7-11 2014 Boston
Chih-Wei Lin, Wei Liu, Armen Asatryan, Andrew Campbell, Sandeep Dutta AbbVie Inc., North Chicago, Illinois, United States
![AASLD1.gif](../images/111414/111414-5/AASLD1.gif)
![AASLD2.gif](../images/111414/111414-5/AASLD2.gif)
![AASLD3.gif](../images/111414/111414-5/AASLD3.gif)
![AASLD4.gif](../images/111414/111414-5/AASLD4.gif)
![AASLD5.gif](../images/111414/111414-5/AASLD5.gif)
![AASLD6.gif](../images/111414/111414-5/AASLD6.gif)
![AASLD7.gif](../images/111414/111414-5/AASLD7.gif)
![AASLD8.gif](../images/111414/111414-5/AASLD8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|